Understanding pain in inflammatory joint diseases
Advancing the Understanding of Pain Mechanisms in Inflammatory Arthritis Towards Precision Pain Management
This project will follow people with inflammatory joint diseases who are starting or switching biological or targeted synthetic DMARDs to try to identify different pain types and see if central sensitization and cognitive function relate to persistent pain.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Diakonhjemmet Hospital Academic / other |
| Locations | 1 site (Oslo) |
| Trial ID | NCT06718569 on ClinicalTrials.gov |
What this trial studies
This is an exploratory, longitudinal observational project enrolling patients with inflammatory joint diseases who initiate or switch biological or targeted synthetic DMARD therapy. Participants will undergo repeated clinical assessments over time to identify phenotypes and endotypes of chronic pain, with a special focus on measures of central sensitization and cognitive functioning. The study will examine how these pain subtypes and risk factors relate to disease activity, treatment response, and daily functioning. Collected data aim to clarify causes and consequences of chronic pain and guide more personalized pain-management approaches.
Who should consider this trial
Good fit: People with inflammatory joint diseases who are initiating or switching biological or targeted synthetic DMARD therapy are the intended participants.
Not a fit: People who are not starting or changing biologic/targeted synthetic DMARDs or whose pain is unrelated to inflammatory joint disease may not receive direct benefit from participation.
Why it matters
Potential benefit: If successful, the findings could lead to more personalized pain management and better matching of treatments for people with inflammatory joint diseases.
How similar studies have performed: Prior work has linked central sensitization and cognitive factors to chronic pain in arthritis, but comprehensive longitudinal phenotyping tied to biologic/targeted synthetic DMARD starts or switches is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients who initiate or switch biological or targeted synthetic DMARDs Exclusion Criteria: * None
Where this trial is running
Oslo
- Diakonhjemmet Hospital — Oslo, Norway (Recruiting)
Study contacts
- Study coordinator: Ida K Haugen, MD PhD
- Email: ida.k.haugen@gmail.com
- Phone: +47 95859884
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.